Apr 5 |
Brookline Capital starts Immunic at buy, cites MS drug candidate
|
Apr 4 |
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors
|
Apr 4 |
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
|
Mar 21 |
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
|
Mar 21 |
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
|
Mar 20 |
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
|
Mar 8 |
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
|
Mar 7 |
Immunic to Participate in Investor and Scientific Conferences in March
|
Feb 29 |
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
|
Feb 29 |
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
|